Erasca Presents Promising Preliminary Phase 1/1b Monotherapy Data for ERAS-007 ERK and ERAS-601 SHP2 Inhibitors Supporting Ongoing and Future Combination Trials
23% of patients with RAS/MAPK-altered non-CRC solid tumors and 44% with BRAF-driven non-CRC solid tumors responded to single agent ERAS-007 or ERAS-601 ERAS-007 and ERAS-601 had favorable... | September 7, 2022
Source: marketscreener.com